Opus Genetics, Inc. Fair Value Adjustment of Warrants
Opus Genetics, Inc. (IRD) reported Fair Value Adjustment of Warrants of -$100.64 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2020-10-29
- Opus Genetics, Inc. fair value adjustment of warrants for the quarter ending 2020-09-30 was -$100.64K.
- Opus Genetics, Inc. fair value adjustment of warrants for the quarter ending 2020-06-30 was $168.70K.
- Opus Genetics, Inc. fair value adjustment of warrants for the quarter ending 2020-03-31 was $58.39K.
- Opus Genetics, Inc. fair value adjustment of warrants for the quarter ending 2019-12-31 was -$82.16K.
- Opus Genetics, Inc. fair value adjustment of warrants for fiscal 2019 was -$2.27M.
- Opus Genetics, Inc. fair value adjustment of warrants for fiscal 2018 was -$5.55M, a 173.03% decline from fiscal 2017.
- Opus Genetics, Inc. fair value adjustment of warrants for fiscal 2017 was $7.59M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$100.64K 10-Q · filed 2020-10-29 | $68.06K derived: sum of 2 quarters · filed 2020-10-29 | $126.46K 10-Q · filed 2020-10-29 | $44.30K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-06-30 | $168.70K 10-Q · filed 2020-08-14 | $227.09K 10-Q · filed 2020-08-14 | $144.94K derived: sum of 3 quarters · filed 2020-08-14 | -$97.92K derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-03-31 | $58.39K 10-Q · filed 2020-05-07 | -$23.76K derived: sum of 2 quarters · filed 2020-05-07 | -$266.62K derived: sum of 3 quarters · filed 2020-10-29 | -$694.11K derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-12-31 | -$82.16K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$325.01K derived: sum of 2 quarters · filed 2020-10-29 | -$752.50K derived: sum of 3 quarters · filed 2020-10-29 | -$2.27M 10-K · filed 2020-02-21 |
| 2019-09-30 | -$242.86K 10-Q · filed 2020-10-29 | -$670.34K derived: sum of 2 quarters · filed 2020-10-29 | -$2.18M 10-Q · filed 2020-10-29 | -$3.98M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | -$427.48K 10-Q · filed 2020-08-14 | -$1.94M 10-Q · filed 2020-08-14 | -$3.73M derived: sum of 3 quarters · filed 2020-08-14 | -$3.02M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | -$1.51M 10-Q · filed 2020-05-07 | -$3.31M derived: sum of 2 quarters · filed 2020-05-07 | -$2.60M derived: sum of 3 quarters · filed 2020-05-07 | -$3.69M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$1.08M derived: sum of 2 quarters · filed 2020-02-21 | -$2.18M derived: sum of 3 quarters · filed 2020-02-21 | -$5.55M 10-K · filed 2020-02-21 |
| 2018-09-30 | $710.07K 10-Q · filed 2019-11-06 | -$385.63K derived: sum of 2 quarters · filed 2019-11-06 | -$3.75M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$1.10M 10-Q · filed 2019-08-07 | -$4.46M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | -$3.37M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $7.59M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |